Unconfigured Ad

Collapse

Relevant events or scientific conferences that may be of interest to the community. (Mgmt reserves right to limit commercial content without approval.)

Forums Topics Posts Last Post
No forums found.
  •  
  • Filter
  • Time
  • Answered
  • Show
  • New Topics
Clear All
new posts
There are no conversations in this channel.
 
  • Filter
  • Time
  • Show
Clear All
new posts
Please log in to your account to view your subscribed posts.
  •  
  • Filter
  • Time
  • Answered
  • Show
  • Sort By
  • Order
Clear All
new posts
Topics Statistics Last Post
Started by Physalia-courses, 11-16-2022, 05:18 AM
0 responses
259 views
1 reaction
Last Post Physalia-courses  
Started by DNSV.EV, 11-11-2022, 09:31 PM
0 responses
199 views
0 reactions
Last Post DNSV.EV
by DNSV.EV
 
Started by Ben3, 11-07-2022, 06:51 AM
0 responses
219 views
0 reactions
Last Post Ben3
by Ben3
 
Started by vivianshaw, 05-31-2022, 12:21 AM
2 responses
280 views
0 reactions
Last Post GaryNicholson  
Started by EMBL-EBI Rebecca, 10-06-2022, 06:22 AM
0 responses
89 views
0 reactions
Last Post EMBL-EBI Rebecca  
Started by DianaMeshch, 09-27-2022, 08:20 AM
0 responses
180 views
0 reactions
Last Post DianaMeshch  
Started by ecSeq Bioinformatics, 05-20-2022, 05:19 AM
3 responses
467 views
1 reaction
Last Post ecSeq Bioinformatics  
Started by alyse_c, 09-16-2022, 06:52 AM
0 responses
169 views
0 reactions
Last Post alyse_c
by alyse_c
 
Started by ecSeq Bioinformatics, 07-10-2022, 11:22 PM
0 responses
220 views
0 reactions
Last Post ecSeq Bioinformatics  
Started by alyse_c, 06-22-2022, 12:41 PM
2 responses
149 views
0 reactions
Last Post alyse_c
by alyse_c
 
No topics found.
  • Filter
  • Time
Clear All
widgetinstance 229 (Webinars) skipped due to lack of content & hide_module_if_empty option.

Recent Articles

Collapse

  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM
  • SEQadmin2
    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
    by SEQadmin2



    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
    07-08-2026, 05:17 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Today, 12:17 PM
0 responses
4 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, Yesterday, 11:41 AM
0 responses
10 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-20-2026, 11:10 AM
0 responses
23 views
0 reactions
Last Post SEQadmin2  
Working...